

Dermatology

Dermatology , DOI: 10.1159/000540920

Received: March 13, 2024

Accepted: August 11, 2024

Published online: October 15, 2024

Systemic Therapy for Atopic Dermatitis in Children and Adolescents:

A United States Expert Consensus

Eichenfield LF, Boguniewicz M, Lauren CT, Leung DYM, Levy ML, Schneider LC, Siegfried EC, Tom WL, Paller AS

ISSN: 1018-8665 (Print), eISSN: 1421-9832 (Online)

<https://www.karger.com/DRM>

Dermatology

Disclaimer:

Accepted, unedited article not yet assigned to an issue. The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publisher and the editor(s). The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to the content.

Copyright:

This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) (<http://www.karger.com/Services/OpenAccessLicense>). Usage and distribution for commercial purposes requires written permission.

© 2024 The Author(s). Published by S. Karger AG, Basel

Accepted Manuscript

Guideline

Systemic Therapy for Atopic Dermatitis in Children and Adolescents: A United States Expert Consensus

Lawrence F. Eichenfield^{a,b}, Mark Boguniewicz^{c,d}, Christine T. Lauren^e, Donald Y. M. Leung^{c,d},
Moise L. Levy^{f,g}, Lynda C. Schneider^h, Elaine C. Siegfried^{i,j}, Wynniss L. Tom^{a,b}, Amy S. Paller^k

^aDepartments of Dermatology and Pediatrics, University of California San Diego, La Jolla, CA;
^bDivision of Pediatric and Adolescent Dermatology, Rady Children's Hospital, San Diego, CA,
USA; ^cDivision of Allergy-Immunology, Department of Pediatrics, National Jewish Health, Denver,
CO, USA; ^dUniversity of Colorado School of Medicine, Denver, CO, USA; ^eDepartments of
Dermatology and Pediatrics, Columbia University, Vagelos College of Physicians and Surgeons,
New York, NY, USA; ^fDepartments of Pediatrics and Internal Medicine (Dermatology), Dell
Medical School at The University of Texas at Austin, Austin, TX, USA; ^gDell Children's Medical
Center, Austin, TX, USA; ^hDivision of Immunology, Boston Children's Hospital, Boston, MA, USA;
ⁱDepartment of Pediatrics, Saint Louis University, St Louis, MO, USA; ^jDepartment of Pediatric
Dermatology, Cardinal Glennon Children's Hospital, St Louis, MO, USA; ^kDepartments of
Dermatology and Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL,
USA.

Running head: Systemic Therapy for Pediatric Atopic Dermatitis

Corresponding Author:

Lawrence F. Eichenfield

Email: leichenfield@rchsd.org

Postcode: Rady Children's Hospital, 3020 Children's Way, Mail Code 5092, San Diego, CA 92123.

Telephone: +1- 858-966-6795.

Keywords: Pediatric atopic dermatitis; systemic therapy; alternative systemic therapy;
conventional systemic therapy; topical therapy.

Key Message: Clinical guidance on use of systemic medications for management of atopic
dermatitis in patients <18yrs.

Abstract

Atopic dermatitis (AD) is a chronic, type-2 mediated, inflammatory skin disease characterized by intense pruritus, disruption of skin barrier function, and immune dysregulation. Management strategies for AD are routinely determined based on disease severity. First-line treatment begins with basic skin care and topical anti-inflammatory medication, which is typically sufficient for the management of mild-to-moderate disease. For those patients with moderate-to-severe disease, systemic therapy is often required. This can involve off-label treatment with conventional immunosuppressant medications. However, this approach is limited by a lack of robust clinical trial data and safety concerns that necessitate close monitoring. The emergence of novel targeted biologics and small molecules to treat AD presents an opportunity to optimize AD management and patient outcomes by offering greater efficacy than traditional immunosuppressants and a favorable safety profile. As the treatment landscape shifts, clinicians can benefit from a standardized process of patient assessment and treatment, along with resources to help maintain contemporary knowledge of available therapeutic options. This United States (US)-based, expert-led consensus used a modified Delphi process to develop core recommendations for the use of systemic medications for the management of pediatric patients <18 years of age with moderate-to-severe AD.

H1: Introduction

Atopic dermatitis (AD) is a chronic, type 2-mediated, inflammatory skin disease that is characterized by intense pruritus and disruption of skin barrier function [1, 2], with a global prevalence of approximately 12–15% in children and adolescents [3].

Many pediatric patients with AD can achieve disease control with basic skin care (i.e., use of low-allergenicity emollients and non-drying bathing practices, and avoiding disease-exacerbating irritants), and adequate use of topical anti-inflammatory medication [4-6]. However, up to one third of children with AD have moderate-to-severe skin disease that is insufficiently controlled with topical therapy and requires systemic treatment [7]. Previously, only oral immunosuppressant drugs, which are limited by variable efficacy and challenging side effects, along with systemic corticosteroids were available in these cases [8, 9]. Since 2017, the development and subsequent implementation of targeted biologic and small molecule agents in routine clinical practice has generated robust data to support the use of these systemic therapeutics in the management of moderate-to-severe AD in patients of all ages, including children [8]. Dupilumab, an anti-interleukin (IL)-4 receptor- α monoclonal antibody that blocks IL-4 and IL-13 signaling, was the first biologic approved for moderate-to-severe AD in children 6 months of age and older [10]. Recently, the IL-13 blocker tralokilumab was approved for children aged 12 years and older [11]. Oral Janus kinase (JAK) inhibitors have subsequently been approved for adolescents and adults, with approval for pediatric patients (≥ 2 years of age) recently granted to the JAK inhibitor, baricitinib, in Europe [8, 12]. Several other novel therapeutic agents are currently under development [8]. With the continued evolution of the AD systemic therapy landscape, healthcare professionals can benefit from a consistent approach to patient assessment and management and should be knowledgeable of when and how to incorporate these therapeutics into treatment pathways. For these reasons, an expert-led consensus was convened to develop recommendations on the use of systemic therapies for pediatric AD.

H1: Methods

In January 2022, a United States (US)-based group of six dermatologists and three allergists convened online to identify key questions concerning the management of moderate-to-severe AD in children and adolescents using systemic therapies. These experts were selected based on their experience, expertise, clinical research activity, publication volume (post 2017) and social media outreach in the context of pediatric AD. For expediency, nurse practitioners, physician assistants and expert adult patients with AD were not included in the consensus process. These stakeholders would be considered for future consensus papers.

A systematic literature review was conducted using Medline and EMBASE to identify publications relevant to four key themes relating to AD management: defining control, current and emerging treatments, referral care pathways, and patient–caregiver experience. Search strings incorporated terms aligned to each of these themes. Initial search results were then filtered for relevance by title and abstract. Full details of the literature search can be found in the Supplementary Material. The expert panel then reviewed the literature results and developed 29 management recommendation statements based on the initial questions in facilitated virtual/email discussions (shown in the Supplementary Material). Draft statements were reviewed and refined independently by the panel in November 2022, and submitted for two rounds of voting using an online platform in January and February 2023.

Consensus was achieved via modified Delphi methodology. During each round of voting, individual members voted anonymously on each statement using a 9-point scale (1 = strong disagreement; 9 = strong agreement). For each statement, consensus for inclusion was considered achieved if $\geq 75\%$ of the experts voted within the 7–9 range on the 9-point scale, or for exclusion if $\geq 75\%$ of the experts voted within the 1–3 range. A second round of voting and refinement was needed for statements that did not achieve the threshold for consensus or exclusion. Details of the final statements are shown in Table 1.

H1: Results

After two rounds of voting, consensus for inclusion was reached on 24 out of 29 statements on the use of systemic therapy for the management of pediatric AD (shown in Table 1, and Supplementary Figures 1 and 2). Nine statements reached a score of 7–9 by 100% of the experts (Table 1). These statements addressed key topics, including: the criteria required for consideration of systemic therapy; the relationship between poor adherence and response to treatment; the importance of coordinated management between primary care providers (PCPs) and secondary care specialists; the potential for disease modification via systemic therapy; along with the existence of knowledge gaps regarding dose escalation in the pediatric population and the lack of comparative data between systemic treatment options. One statement was excluded as the experts agreed that the optimal approach for tapering systemic therapy was unclear. The overall approach was discussed, but in-depth recommendations for specific therapies were beyond the scope of this consensus. Further work may explore specific tapering recommendations for given systemic therapies.

H2: When to consider systemic therapy

Management decisions, including when to initiate systemic therapy, should be made collaboratively between clinicians and the patients or caregivers [4]. Multidisciplinary approaches to AD care are common in view of the complex interplay between the multiple factors affecting AD control, and the broad range of expertise and support that patients and families need to manage AD effectively. Such an approach often includes medical evaluation and management by an AD specialist, education and nursing care, psychological and behavioral

support, and nutritional assessment and guidance [13]. The AD specialist may be an allergist or dermatologist, and often a collaboration between these specialties [13]. If the patient has poorly controlled AD despite optimized skin care and medical management with topical therapies, engagement of an allergist to consider comorbidities and allergic triggers (e.g., allergy testing and possible food elimination/challenges) is advisable [13, 14].

Factors to consider before initiating systemic therapy include disease severity, effect to quality of life, associated comorbidities, degree of response to topical therapy, disease-exacerbating factors (such as allergies, allergic contact dermatitis, and irritants), and the risk–benefit ratio of both systemic agents and topical agents [9]. Phototherapy may also be considered as a treatment option in these cases, but requires frequent office visits 2–3 times weekly and can be limited in its capability to manage acute flares due to the time delay between treatment onset and disease control [15, 16].

Systemic therapy may also be considered if excessive amounts of topical corticosteroids (TCSs) are needed to control persistent or frequently recurring AD. Ongoing daily or increasingly frequent use of high potency TCSs, or using more than the recommended quantity, can result in adverse effects including skin thinning, hypopigmentation, striae formation, and percutaneous absorption with potential systemic toxicity [17]. It is therefore advised that clinicians monitor TCS use closely. For children who use potent TCSs chronically but show no evidence of local or systemic side effects, it is unclear how "excessive use" should be defined. In these cases, the clinician must decide whether switching to a systemic therapy would provide greater benefit and/or safety to the patient than continuing with the current TCS application regime.

Total corticosteroid burden, including the use of oral/systemic, intranasal, inhaled, and TCSs, should be factored into the decision to initiate non-corticosteroid systemic therapy. This is particularly important when evaluating patients receiving corticosteroids for comorbid conditions, e.g., asthma and chronic rhinitis, as these patients may be candidates for earlier initiation of non-corticosteroid based systemic therapy to minimize cumulative corticosteroid exposure [18, 19].

H2: Choice of systemic therapy

Systemic corticosteroid (SCS) use is generally not recommended for pediatric patients with AD and should be restricted to short-term use. Although short-term SCS use is commonly prescribed for managing AD flares, the most recent AD guidelines recommend against this approach as discontinuation can result in rebound disease worsening [7, 20, 21]. Long-term SCS use is contraindicated due to significant safety risks which include adrenal suppression, changes in linear growth, hyperglycemia, and inappropriate weight gain [20, 21]. In certain clinical settings, SCSs may be used selectively as a bridging therapy during initiation of more sustainable systemic therapies [20].

Factors to take into consideration when choosing a systemic therapy include AD phenotype, the presence of comorbidities, the risk–benefit profile of treatments, patient preferences (e.g., oral vs injectable therapy), the need for laboratory monitoring, drug interactions, cost, adverse events, and access to therapy. Some novel systemic therapeutics used to treat AD may also be effective in reducing the severity of atopic comorbidities (e.g., asthma, allergies, eosinophilic esophagitis) [10, 22, 23]. Associated extracutaneous atopic diseases should, therefore, be considered when making medical decisions about the most appropriate treatment. As AD is a heterogeneous disease with a variety of clinical presentations, it is important to identify any unique features that may inform appropriate treatment selection

[24-26]. Patient age should also be considered in the context of age-restricted medication indication, difficulty with injections and/or venipuncture, and childbearing potential [27, 28].

Conventional systemic therapies such as cyclosporine and methotrexate have been used off-label for decades to treat moderate-to-severe AD, with well-recognized risks and mitigation strategies [29, 30]. Azathioprine and mycophenolate mofetil have also been used off-label but less frequently [29, 31]. Although these immunosuppressants can provide therapeutic benefit for refractory AD, they have been associated with safety concerns that require close laboratory monitoring [31, 32]. As an increasing number of alternative therapies for AD have been approved, the use of conventional immunosuppressant medications has decreased. Nonetheless, careful consideration should be given to when these agents should be used, such as when there are concomitant conditions (e.g., juvenile arthritis, inflammatory bowel disease) that could be managed by these drugs [33].

Biologic drugs or JAK inhibitors should be considered as a first-line systemic treatment for moderate-to-severe AD, unless contraindicated, in instances where standard topical therapies have proven insufficient/inadequate for disease control. Dupilumab, an IL-4 receptor- α antagonist, has shown sustained symptom reduction in children ≥ 6 months of age and is currently the only approved biologic for pediatric AD ≥ 6 months of age in major world regions including the US, Europe, United Kingdom, Japan, China, and Australia [10, 34-38]. Recently, the IL-13 blocker tralokilumab was approved for children aged ≥ 12 years with AD [11]. In addition, a number of other promising biologic therapies targeting IL-13 and IL-31 are undergoing clinical and regulatory evaluation in the US for pediatric indications [6]. Biologic drugs have a more favorable safety profile than conventional therapies, with fewer immunosuppressive adverse events [39]. They are, however, associated with increased rates of conjunctivitis, although most cases are managed with ophthalmic agents and do not require stopping the biologic drug [10].

Currently, JAK inhibitors (abrocitinib and upadacitinib) approved in the US are indicated for patients ≥ 12 years of age with moderate-to-severe AD whose disease is not adequately controlled with other systemic drugs, including biologics, or when the use of those therapies is inadvisable [23, 39, 40]. Several more JAK inhibitors are in development [41]. These agents have been associated with a rapid reduction in pruritus and high response rates [42-44]. Adverse effects include nausea, acne, headaches, and impaired immune function requiring laboratory monitoring [42, 45]. Uncommon but serious adverse effects include cardiac events, cancer, blood clots, and increased all-cause mortality, prompting a drug-class-associated black box warning by the US Food and Drug Administration (FDA) [46, 47]. Clinicians must discuss the risk-benefit profile with all potential JAK inhibitor candidates before initiating patient treatment with a therapeutic agent from this class. Furthermore, patients treated with oral JAK inhibitors should undergo appropriate screening and lab monitoring [39].

Comparative evidence for the use of conventional and novel systemic therapies in AD is limited, especially in children [48]. As systemic therapy options continue to expand, comparative data will be essential to inform further comprehensive guidance for clinicians.

H2: When to escalate systemic therapy

Evidence on specific escalation of therapy across all pediatric age groups (often divided into <2 years, 2-6 years, and 6-12 years in clinical practice) needs to be generated. This includes clinical trial data, pharmacokinetic studies, and real-world studies from clinical practice settings. Generating this evidence in the pediatric population will help inform clinicians on how to optimize and tailor systemic therapy in difficult to treat patients.

Clinicians should refer to specific prescribing information, data from clinical trials, and relevant guidelines where available to guide treatment escalation. Clinicians should be aware that options to escalate treatment will vary depending on factors such as the patient's age and therapeutic needs, as well as medical insurance coverage, which may limit treatment access [31, 49]. The clinician should also consider whether there is evidence to support dose escalation for a given systemic therapy in pediatric patients, as well as the likelihood and magnitude of increased efficacy if the dose of treatment is increased [50-53]. For pediatric patients with an inadequate response to initial systemic treatment, a dose increase or an increase in administration frequency may be considered [52]. For instance, in young children receiving treatment with dupilumab every 4 weeks, dosing could be escalated to every 2 weeks; however, this regimen would be off-label [10]. In patients ≥ 12 years of age, both abrocitinib and upadacitinib are administered with an initial standard dose (100mg daily for abrocitinib and 15mg daily for upadacitinib) in adult and adolescent patients, with subsequent dose escalation (200mg and 30mg, respectively) recommended in patients unresponsive to the initial dosing regimen [23, 40].

H2: When to consider an alternative systemic therapy

Alternative treatment may be considered for patients whose AD is not adequately controlled on the initially recommended systemic therapy, however, potential contributory factors to poor response should be reviewed beforehand. Inadequate response to systemic treatment suggests the need for an alternate medication or combination therapy [54-56]. However, data on the safety and efficacy of combination treatments are limited at present. Prior to changing treatment, factors contributing to an inadequate therapeutic response should be considered (e.g., poor adherence, concomitant infection, contact allergy, co-existing psoriasis, and suboptimal treatment duration) [6, 9, 55]. When switching to a new systemic treatment, it is recommended to continue topical therapy until the new systemic medication is fully effective, or as an adjunctive therapy during ongoing systemic therapy [6, 15, 57]. For patients who are switching from another systemic therapy, consideration should be given to a brief (1–2 months) overlap period where the original systemic medication is tapered and the new systemic medication is allowed time to take effect.

H2: Tapering and discontinuation of systemic therapy

Treatment taper may be considered after the skin has remained clear or almost clear for several months, or in response to safety and tolerability concerns, but the optimal approach has not been defined. The timing of medication taper depends on the reason: prolonged skin clearance or concerns about safety or tolerability [11, 31, 39, 58-61]. The taper regimen depends on the systemic drug being used, and may involve increasing the time interval between doses or reducing the dose quantity. There is no specific prescribing information for the tapering of biologics in AD, but off-label extension of dosing intervals can be used in clinical practice where appropriate [62]. Additionally, the frequency at which dose tapering should occur has not been defined. Theoretical concerns include the potential for developing anti-drug antibodies when using long dosing intervals, or with frequent stopping/starting of biologics [63].

Discontinuing systemic therapy may result in disease recurrence, from as early as 2 weeks with cyclosporine, to 3 months or more with methotrexate or novel therapies such as dupilumab and abrocitinib [64-68]. It is important that clinicians are proactive and cautious when formulating treatment strategies, to ensure that the most suitable systemic therapy is selected and the likelihood for discontinuation due to adverse effects and restricted accessibility is minimized. Patients should be monitored closely if treatment is stopped and a post-discontinuation management plan should be in place.

H2: Adherence to systemic therapy

Inadequate response to systemic therapy may be associated with poor adherence.

Although poor adherence is less frequently encountered with systemic therapy than with topical therapy, adherence may be difficult to monitor and can be overlooked [69, 70]. Adherence can vary between different systemic agents, with patients on immunosuppressants demonstrating significantly lower compliance at 12 months compared to patients receiving dupilumab [71, 72]. Reasons for inadequate adherence to treatment are varied, including concerns regarding adverse effects, inadequate patient/caregiver education, child resistance to treatment, a lack of trust in/rapport with the clinician, and high out-of-pocket costs and/or limitations to treatment access [55, 69-72].

Ongoing education and support are important to help to ensure patients and caregivers are comfortable with, and adherent to, systemic treatment.

Education is critical for successful treatment of AD, and should cover information surrounding the disease itself, the treatments being used, and how to apply (topical treatments) or administer (injectable biologics) these treatments [73, 74]. This should include tips on managing the itch–scratch cycle, improving sleep, engaging children in their treatment plan, and managing AD at school and daycare [75]. As injections can be distressing for children, coaching on what to expect, the potential benefits, and giving the child some control around treatment administration (where to give the injection, where to sit, etc.) can be helpful [76]. In addition to anticipatory guidance and education, creating a routine, using distraction techniques, and positive rewards can lead to successful administration [75].

H2: Immunizations

When prescribing systemic therapy to pediatric patients, the potential for an attenuated vaccine response needs to be considered. There is currently limited evidence to guide co-administration of systemic therapies and vaccines. Bridging this evidence gap is critical as many routine vaccinations are scheduled within the first few years of life [77]. In the interim, evidence may be extrapolated from data on the use of these systemic therapies in other diseases (adult or pediatric), or from observations of adults with AD.

Based on studies of other diseases, systemic therapies including methotrexate, SCSs and JAK inhibitors, may reduce protective antibody titers in adults following vaccination [77-84]. In addition, JAK inhibitors significantly increase the risk of herpes zoster reactivation [85-87]. For these reasons, international expert groups recommend that vaccines are administered before starting treatment wherever possible, with a longer delay to initiation of treatment if administering a live-attenuated vaccine as opposed to an inactivated vaccine [88, 89]. Furthermore, a European panel recommends that inactivated vaccines can be safely administered in immunosuppressed pediatric patients with autoimmune inflammatory rheumatic disease, except when patients are receiving high doses of glucocorticoids or B-cell depleting therapies [90]. The safety of co-administration with live-attenuated vaccines is not currently known, and is usually avoided due to the theoretical risk of infection with the attenuated pathogen [88, 89, 91]. However, with delaying/avoiding particular vaccines, there is also a risk associated with not being immunized [91, 92]. Overall, data suggest that inactivated vaccines may be safely administered while receiving systemic treatment for AD, but further consideration and a thorough risk–benefit analysis needs to be undertaken for live-attenuated vaccines [88, 89].

Biologic therapy does not need to be interrupted for administration of inactivated vaccines but the safety of co-administration with live-attenuated vaccines is not known.

General recommendations for patients who are treated with conventional systemic

immunosuppressants are to complete age-appropriate vaccinations according to immunization guidelines prior to starting therapy, where possible, and to avoid live-attenuated vaccines during immunosuppressive treatment [93-95]. Prior to initiating an approved JAK inhibitor, or biologic, current regulatory labeling states that patients should be brought up to date with all immunizations, with the avoidance of live vaccines during or immediately prior to treatment [10, 23, 40]. Hesitancy around live-attenuated vaccination during biologic therapy may stem from a lack of data on the true risk of pathogen reactivation during co-administration of live vaccines. However, data from adults with moderate-to-severe AD suggest that treatment with dupilumab may not weaken the immune response, nor reduce protective antibody titers, following inactivated vaccine administration [96]. Furthermore, as dupilumab exerts an inhibitory effect on type 2 cytokines, it is suggested that treatment may improve the patient's functional response to vaccination by shifting the cytokine milieu toward a T helper type 1-mediated antiviral response [96]. A recent prospective case series of nine children with severe AD treated with dupilumab who received the live-attenuated measles, mumps, and rubella (MMR) vaccine, with or without the live-attenuated varicella vaccine, found no vaccine-related viral infections or serious adverse events within the 4-week post-vaccination period [97]. In five of the nine cases, vaccination occurred less than 12 weeks after cessation of dupilumab (deviation from study protocol) and dupilumab was resumed 2–43 days thereafter [97]. Based on available data regarding the timing of live vaccines around dupilumab therapy, co-administering live-attenuated vaccines and dupilumab may be considered on a case-by-case basis after a thorough risk–benefit analysis [97, 98]. Many of the expert panel have reported live vaccine administration 1 month after stopping dupilumab, and then re-initiating dupilumab 1 month post-immunization. As primary prescribers of biologics, specialists should remain knowledgeable and up to date on evolving vaccination recommendations for biologics currently approved for AD, along with those that may emerge in the future.

H2: Involvement of primary care

PCPs play an important role in the management of AD. As the first point of care for most patients with AD, PCPs most often treat patients with mild-to-moderate disease [53, 99], refer those requiring specialist care, provide ongoing maintenance care, and manage acute infections [53, 99]. For this reason, **it is important for PCPs to understand AD pathophysiology and diagnosis, as well as treatment strategies and potential treatment-related adverse effects.** As PCPs are primarily community-based, their participation within the shared care system can also help foster a proactive, collaborative, and patient-centered approach to AD management [53, 99]. Specialists should effectively coordinate and collaborate with PCPs to achieve optimal patient outcomes.

Ongoing consultation and dialogue between the PCP, families, and specialists may be helpful in determining effective treatment approaches. For example, while PCPs do not typically prescribe systemic treatments for AD, they should be informed when these therapies are being considered or initiated, as this may affect other treatments or conditions. They may also be called upon to help monitor or address side effects or complications.

H2: Disease-modifying effect

The ability to use systemic therapy such as biologics in patients as young as 6 months of age offers the potential for a disease-modifying effect. However, as AD is a disease that can spontaneously improve with age in some patients, it may prove difficult to establish the disease-modifying effects of systemic therapy [8].

The impact of early intervention on the natural history of disease and the development of AD-associated morbidities is not currently known. In other chronic diseases, such as

rheumatoid arthritis, selected systemic treatments are known to improve the lifetime risk of developing commonly associated comorbidities [100, 101]. Atopy typically manifests in early childhood with AD and food allergy, and often progresses to include other atopic morbidities, such as rhinitis, asthma, and eosinophilic esophagitis [102, 103]. Researchers have proposed that by preventing or treating AD in early infancy or childhood, it may be possible to prevent the development of food allergy and atopic respiratory diseases. Some studies suggest the development of atopic disease later in life can be predicted by the presence of early onset and severe AD, along with immunoglobulin E sensitization (potentially facilitated by AD-associated skin barrier dysfunction) [104, 105]. As type 2 inflammatory cytokines, especially IL-4, are known to mediate both immunoglobulin E sensitization and AD pathogenesis, modulation of IL-4 signaling via dupilumab may present a therapeutic approach to halt the atopic march [104-106]. A recent meta-analysis of clinical trial data found that dupilumab reduced the incidence of new allergies and the worsening of pre-existing allergic conditions in patients with AD [104]. This benefit was most prominent in younger patients (<18 years), especially those with early onset of AD (<2 years) [104]. This protective effect persisted, in an attenuated form, after discontinuation, suggesting a potential disease-modifying effect [104]. Although a longer follow-up period will be required, these results provide positive data following previous unsuccessful attempts to halt the atopic march with other systemic agents [104]. It is also important to note that AD is commonly associated with non-atopic morbidities (e.g., neuropsychiatric conditions), but there is currently little data on how early successful AD management influences their development.

H1: Conclusions

The physical signs and symptoms of AD, its associated comorbidities, and its psychosocial consequences constitute a substantial burden on affected children and their parents/caregivers. As the systemic treatment landscape for moderate-to-severe AD continues to evolve, it is hoped that therapies that offer greater efficacy and more favorable risk–benefit profiles will help individuals with AD achieve disease control where topical and adjunctive therapies alone have not been sufficient. The recommendations provided here are aimed at guiding clinicians in optimizing outcomes for their patients.

Statements

Conflict of Interest Statement

Lawrence Eichenfield reports research grants from AbbVie, Amgen, Castle, Dermavant, Galderma, LEO and Pfizer; personal/consulting fees from AbbVie, Aslan, Dermavant, Forte; Galderma, Incyte, Janssen, LEO Pharma, Eli Lilly and Company, Pfizer, Incyte, Regeneron, and Sanofi; and has been on the Board of Directors and owns stocks with Forte.

Mark Boguniewicz reports grants from Regeneron, Sanofi, and Incyte and has participated as a consultant or adviser for AbbVie, Amgen, Dermavant, Eli Lilly and Company, Incyte, Janssen, LEO Pharma, Pfizer, Regeneron and Sanofi Genzyme.

Christine Lauren has no conflicts of interest to disclose.

Donald Leung reports consulting with Aslan Pharmaceuticals, Evommune, Genentech, LEO Pharma, Regeneron Pharmaceuticals, Inc., has been a Principal Investigator in clinical trials Incyte, and holds a research grant with Sanofi Genzyme.

Moise Levy reports advisory board involvement and consultancy for Cassiopea, Regeneron, and UCB, was an investigator for Fibrocell, Galderma, Janssen, and Pfizer, was on a data safety monitoring board for Novan, and was a section editor and author for UpToDate.

Lynda Schneider reports grants from Pfizer, participation on advisory boards for AbbVie, Amagma Therapeutics, DAIT/NIAID, LEO Pharma, and Sanofi and has been an Investigator on a clinical trial for Regeneron.

Elaine Siegfried reports working with Dermavant, Eli Lilly, GlaxoSmithKline, Pfizer, Regeneron Pharmaceuticals, Inc., and as a consultant to Verrica Pharmaceuticals.

Wynniss Tom reports being an investigator for Regeneron, AbbVie, Janssen, Dermira, Lilly, and a Data Safety Committee Member for LEO Pharma.

Amy Paller reports being an investigator or consultant for AbbVie, Boehringer-Ingelheim, Bristol Myers Squibb, Catawba, Dermavant, Eli Lilly, Galderma, Janssen, LEO Pharma, Novartis, Regeneron, Sanofi/Genzyme, Seanergy, and UCB; and has served on AbbVie and Galderma Data Safety Monitoring Boards.

Funding Sources

The consensus development was funded by Sanofi and Regeneron. Sanofi and Regeneron had no role in the development of the consensus recommendations; collection, management, analysis, and interpretation of the literature; preparation, review, or approval of the manuscript. The authors received no financial compensation for the development and publication of this article. Medical writing support was provided by Lucid Group and funded by Sanofi, Cambridge MA, United States and Regeneron, in accordance with Good Publication Practice 2022 (GPP 2022) guidelines.

Author Contributions

Prof Lawrence Eichenfield, Prof Mark Boguniewicz, Dr Christine Lauren, Prof Donald Leung, Prof Moise Levy, Prof Lynda Schneider, Prof Elaine Siegfried, Dr Wynniss Tom, and Prof Amy Paller all joined steering committee meetings to develop the consensus statements, and critically reviewed and revised the manuscript. All authors approved the final manuscript as submitted and agreed to be accountable for all aspects of the work.

References

1. Eichenfield LF, Tom WL, Chamlin SL, Feldman SR, Hanifin JM, Simpson EL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. *J Am Acad Dermatol*. 2014;70(2):338-51.
2. Paller AS, Mina-Osorio P, Vekeman F, Boklage S, Mallya UG, Ganguli S, et al. Prevalence of type 2 inflammatory diseases in pediatric patients with atopic dermatitis: Real-world evidence. *J Am Acad Dermatol*. 2022;86(4):758-65.
3. Silverberg JI, Barbarot S, Gadkari A, Simpson EL, Weidinger S, Mina-Osorio P, et al. Atopic dermatitis in the pediatric population: A cross-sectional, international epidemiologic study. *Ann Allergy Asthma Immunol*. 2021;126(4):417-28.e2.
4. Butala S, Paller AS. Optimizing topical management of atopic dermatitis. *Ann Allergy Asthma Immunol*. 2022;128(5):488-504.
5. Glines KR, Stiff KM, Freeze M, Cline A, Strowd LC, Feldman SR. An update on the topical and oral therapy options for treating pediatric atopic dermatitis. *Expert Opin Pharmacother*. 2019;20(5):621-29.
6. Eichenfield LF, Stripling S, Fung S, Cha A, O'Brien A, Schachner LA. Recent developments and advances in atopic dermatitis: A focus on epidemiology, pathophysiology, and treatment in the pediatric setting. *Paediatr Drugs*. 2022;24(4):293-305.
7. Drucker AM, Ellis AG, Bohdanowicz M, Mashayekhi S, Yiu ZZN, Rochweg B, et al. Systemic immunomodulatory treatments for patients with atopic dermatitis: A systematic review and network meta-analysis. *JAMA Dermatol*. 2020;156(6):659-67.
8. Lockhart MK, Siegfried EC. Evolving landscape of systemic therapy for pediatric atopic dermatitis. *Dermatol Clin*. 2022;40(2):137-43.
9. Simpson EL, Bruin-Weller M, Flohr C, Ardern-Jones MR, Barbarot S, Deleuran M, et al. When does atopic dermatitis warrant systemic therapy? Recommendations from an expert panel of the International Eczema Council. *J Am Acad Dermatol*. 2017;77(4):623-33.
10. Dupixent (dupilumab) U.S PI. Regeneron; October 2023. https://www.regeneron.com/downloads/dupixent_fpi.pdf. Accessed July 2023.
11. ADBRY® (tralokinumab-ldrm). Highlights of prescribing information. Pharma L; March 2023. <https://mc-df05ef79-e68e-4c65-8ea2-953494-cdn-endpoint.azureedge.net/-/media/corporatecommunications/us/therapeutic-expertise/our-product/adbrypi.pdf?rev=65a4030a7140473198c24e795b9c19f1>. Accessed January 2024.
12. Olumiant® (baricitinib). Summary of Product Characteristics. Company ELA; October 2023. https://www.ema.europa.eu/en/documents/product-information/olumiant-epar-product-information_en.pdf. Accessed January 2024.
13. LeBovidge JS, Elverson W, Timmons KG, Hawryluk EB, Rea C, Lee M, et al. Multidisciplinary interventions in the management of atopic dermatitis. *J Allergy Clin Immunol*. 2016;138(2):325-34.
14. Singh AM, Anvari S, Hauk P, Lio P, Nanda A, Sidbury R, et al. Atopic Dermatitis and Food Allergy: Best Practices and Knowledge Gaps-A Work Group Report from the AAAAI Allergic Skin Diseases Committee and Leadership Institute Project. *J Allergy Clin Immunol Pract*. 2022;10(3):697-706.

15. Sidbury R, Davis DM, Cohen DE, Cordoro KM, Berger TG, Bergman JN, et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. *J Am Acad Dermatol*. 2014;71(2):327-49.
16. Dayal S, Pathak K, Sahu P, Jain VK. Narrowband UV-B phototherapy in childhood atopic dermatitis: efficacy and safety. *An Bras Dermatol*. 2017;92(6):801-06.
17. Coondoo A, Phiske M, Verma S, Lahiri K. Side-effects of topical steroids: A long overdue revisit. *Indian Dermatol Online J*. 2014;5(4):416-25.
18. Siegfried EC, Jaworski JC, Kaiser JD, Hebert AA. Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis. *BMC Pediatr*. 2016;16:75.
19. Fonacier L, Banta E, Mawhirt S, Noor I, Feldman E, Armstrong Martin R, et al. Capturing total steroid burden in patients with atopic dermatitis and asthma. *Allergy Asthma Proc*. 2022;43(5):454-60.
20. Drucker AM, Eyerich K, de Bruin-Weller MS, Thyssen JP, Spuls PI, Irvine AD, et al. Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement. *Br J Dermatol*. 2018;178(3):768-75.
21. Yu SH, Drucker AM, Lebwohl M, Silverberg JI. A systematic review of the safety and efficacy of systemic corticosteroids in atopic dermatitis. *J Am Acad Dermatol*. 2018;78(4):733-40.e11.
22. Panettieri RA, Jr., Sjöbring U, Péterffy A, Wessman P, Bowen K, Piper E, et al. Tralokinumab for severe, uncontrolled asthma (STRATOS 1 and STRATOS 2): two randomised, double-blind, placebo-controlled, phase 3 clinical trials. *Lancet Respir Med*. 2018;6(7):511-25.
23. Rinvoq® (upadacitinib). Highlights of prescribing information. AbbVie; November 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/211675s019lbl.pdf. Accessed January 2024.
24. Raimondo A, Lembo S. Atopic dermatitis: Epidemiology and clinical phenotypes. *Dermatol Pract Concept*. 2021;11(4):e2021146.
25. Facheris P, Jeffery J, Del Duca E, Guttman-Yassky E. The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment. *Cell Mol Immunol*. 2023;20(5):448-74.
26. Czarnowicki T, He H, Krueger JG, Guttman-Yassky E. Atopic dermatitis endotypes and implications for targeted therapeutics. *J Allergy Clin Immunol*. 2019;143(1):1-11.
27. Balakirski G, Novak N. Atopic dermatitis and pregnancy. *J Allergy Clin Immunol*. 2022;149(4):1185-94.
28. van der Rijst LP, van Royen-Kerkhof A, Pasmans SGMA, Schappin R, de Bruin-Weller MS, de Graaf M. Biologicals for pediatric patients with atopic dermatitis: practical challenges and knowledge gaps. *J Dermatolog Treat*. 2023;34(1):2254567.
29. Wolverton SE. *Comprehensive dermatologic drug therapy*. 4th Edition. Elsevier; 2019.
30. Harper JI, Ahmed I, Barclay G, Lacour M, Hoeger P, Cork MJ, et al. Cyclosporin for severe childhood atopic dermatitis: short course versus continuous therapy. *Br J Dermatol*. 2000;142(1):52-8.
31. Boguniewicz M, Fonacier L, Guttman-Yassky E, Ong PY, Silverberg J, Farrar JR. Atopic dermatitis yardstick: Practical recommendations for an evolving therapeutic landscape. *Ann Allergy Asthma Immunol*. 2018;120(1):10-22.e2.

32. Megna M, Napolitano M, Patruno C, Villani A, Balato A, Monfrecola G, et al. Systemic treatment of adult atopic dermatitis: A review. *Dermatol Ther (Heidelb)*. 2017;7(1):1-23.
33. Paller A, Jaworski JC, Simpson EL, Boguniewicz M, Russell JJ, Block JK, et al. Major comorbidities of atopic dermatitis: beyond allergic disorders. *Am J Clin Dermatol*. 2018;19(6):821-38.
34. Paller AS, Simpson EL, Siegfried EC, Cork MJ, Wollenberg A, Arkwright PD, et al. Dupilumab in children aged 6 months to younger than 6 years with uncontrolled atopic dermatitis: a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*. 2022;400(10356):908-19.
35. Dupixent® (dupilumab) recommended for expanded EU approval by the CHMP to treat children as young as six months old with severe atopic dermatitis. Sanofi; 2023. <https://www.sanofi.com/en/media-room/press-releases/2023/2023-01-27-06-00-00-2596599>. Accessed
36. AD treatment Dupixent approved for use in China for young children. CHINADAILY; 2023. <https://www.chinadaily.com.cn/a/202305/31/WS6476e130a3107584c3ac324a.html#:~:text=French%20pharmaceutical%20company%20Sanofi%20announced,six%20months%20old%20and%20five>. Accessed May 2024.
37. Australian Government Department of Health and Aged Care. DUPIXENT (Sanofi-Aventis Australia Pty Ltd). <https://www.tga.gov.au/resources/prescription-medicines-registrations/dupixent-sanofi-aventis-australia-pty-ltd-4>. 2023. Accessed May 2024
38. European Medicines Agency (EMA). Dupixent® (dupilumab). Summary of Product Characteristics. https://www.ema.europa.eu/en/documents/product-information/dupixent-epar-product-information_en.pdf. October 2017. Accessed May 2024
39. Boguniewicz M, Fonacier L, Guttman-Yassky E, Ong PY, Silverberg JI. Atopic Dermatitis Yardstick update. *Ann Allergy Asthma Immunol*. 2023;130(6):811-20.
40. CIBINQO® (abrocitinib). Highlights of prescribing information. Pfizer; January 2022. https://cdn.pfizer.com/pfizercom/USPI_Med_Guide_CIBINQO_Abrocitinib_tablet.pdf. Accessed January 2024.
41. Mikhaylov D, Ungar B, Renert-Yuval Y, Guttman-Yassky E. Oral Janus kinase inhibitors for atopic dermatitis. *Ann Allergy Asthma Immunol*. 2023;130(5):577-92.
42. Reich K, Thyssen JP, Blauvelt A, Eyerich K, Soong W, Rice ZP, et al. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial. *Lancet*. 2022;400(10348):273-82.
43. Silverberg JI, Hong HC, Thyssen JP, Calimlim BM, Joshi A, Teixeira HD, et al. Comparative efficacy of targeted systemic therapies for moderate to severe atopic dermatitis without topical corticosteroids: systematic review and network meta-analysis. *Dermatol Ther (Heidelb)*. 2022;12(5):1181-96.
44. Paller AS, Ladizinski B, Mendes-Bastos P, Siegfried E, Soong W, Prajapati VH, et al. Efficacy and safety of upadacitinib treatment in adolescents with moderate-to-severe atopic dermatitis: analysis of the Measure Up 1, Measure Up 2, and AD Up randomized clinical trials. *JAMA Dermatol*. 2023;159(5):526-35.
45. Vakharia PP, Silverberg JI. New and emerging therapies for paediatric atopic dermatitis. *Lancet Child Adolesc Health*. 2019;3(5):343-53.
46. US Food and Drug Administration (FDA). Janus Kinase (JAK) inhibitors: Drug Safety Communication - FDA Requires Warnings about Increased Risk of Serious Heart-related Events, Cancer, Blood Clots, and Death. <https://www.fda.gov/safety/medical-product-safety-information/janus-kinase-jak-inhibitors-drug-safety-communication-fda-requires-warnings-about-increased-risk>. September 2021. Accessed August 2023

47. Samuel C, Cornman H, Kambala A, Kwatra SG. A review on the safety of using JAK inhibitors in dermatology: Clinical and laboratory monitoring. *Dermatol Ther (Heidelb)*. 2023;13(3):729-49.
48. Totri CR, Eichenfield LF, Logan K, Proudfoot L, Schmitt J, Lara-Corrales I, et al. Prescribing practices for systemic agents in the treatment of severe pediatric atopic dermatitis in the US and Canada: The PeDRA TREAT survey. *J Am Acad Dermatol*. 2017;76(2):281-85.
49. Siegfried EC, Paller AS, Mina-Osorio P, Vekeman F, Kaur M, Mallya UG, et al. Effects of variations in access to care for children with atopic dermatitis. *BMC Dermatol*. 2020;20(1):24.
50. Broderick CA, H; Feeney, C; de Lusigan, S; Florh, C. Paediatric atopic dermatitis incidence and treatment patterns in the UK: Results from a large population-based primary care cohort study (2009-2018). *Pediatric Dermatology*. 2021;38(S1):12-91.
51. de Lusignan S, Alexander H, Broderick C, Dennis J, McGovern A, Feeney C, et al. Patterns and trends in eczema management in UK primary care (2009-2018): A population-based cohort study. *Clin Exp Allergy*. 2021;51(3):483-94.
52. Brar KK, Nicol NH, Boguniewicz M. Strategies for successful management of severe atopic dermatitis. *J Allergy Clin Immunol Pract*. 2019;7(1):1-16.
53. Meadows S, Fending D, Boguniewicz M. Collaboration in best practices for care of patients with atopic dermatitis. *J Allergy Clin Immunol Pract*. 2016;4(2):347-9.e1.
54. Davari DR, Nieman EL, McShane DB, Morrell DS. Current perspectives on the systemic management of atopic dermatitis. *J Asthma Allergy*. 2021;14:595-607.
55. Johnson BB, Franco AI, Beck LA, Prezzano JC. Treatment-resistant atopic dermatitis: challenges and solutions. *Clin Cosmet Investig Dermatol*. 2019;12:181-92.
56. De Bruin-Weller M, Biedermann T, Bissonnette R, Deleuran M, Foley P, Girolomoni G, et al. Treat-to-target in atopic dermatitis: An international consensus on a set of core decision points for systemic therapies. *Acta Derm Venereol*. 2021;101(2):adv00402.
57. Eichenfield LF, Tom WL, Berger TG, Krol A, Paller AS, Schwarzenberger K, et al. Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies. *J Am Acad Dermatol*. 2014;71(1):116-32.
58. Spekhorst LS, Bakker D, Drylewicz J, Rispens T, Loeff F, Boesjes CM, et al. Patient-centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis. *Allergy*. 2022;77(11):3398-407.
59. Patruno C, Potestio L, Fabbrocini G, Napolitano M. Dupilumab dose spacing after initial successful treatment or adverse events in adult patients with atopic dermatitis: A retrospective analysis. *Dermatol Ther*. 2022;35(12):e15933.
60. Jendoubi F, Shourik J, Seneschal J, Giordano-Labadie F, Raison-Peyron N, Du-Thanh A, et al. Longer dupilumab dosing intervals in adult patients with atopic dermatitis: experience from a French multicentre retrospective cohort study. *Br J Dermatol*. 2022;187(4):602-03.
61. Spekhorst LS, Boesjes CM, Loman L, Zuithoff NPA, Bakker DS, Kamphuis E, et al. Successful tapering of dupilumab in patients with atopic dermatitis with low disease activity: a large pragmatic daily practice study from the BioDay registry. *Br J Dermatol*. 2023;189(3):327-35.

62. US Food and Drug Administration (FDA). "Off-Label" and Investigational Use Of Marketed Drugs, Biologics, and Medical Devices. <https://public4.pagefreezer.com/content/FDA/01-02-2023T10:30/https://www.fda.gov/regulatory-information/search-fda-guidance-documents/label-and-investigational-use-marketed-drugs-biologics-and-medical-devices>. January 1998. Accessed August 2023
63. Vaisman-Mentesh A, Gutierrez-Gonzalez M, DeKosky BJ, Wine Y. The molecular mechanisms that underlie the immune biology of anti-drug antibody formation following treatment with monoclonal antibodies. *Front Immunol*. 2020;11.
64. Granlund H, Erkkö P, Sinisalo M, Reitamo S. Cyclosporin in atopic dermatitis: time to relapse and effect of intermittent therapy. *Br J Dermatol*. 1995;132(1):106-12.
65. Law Ping Man S, Bouzillé G, Beneton N, Safa G, Dupuy A, Droitcourt C. Drug survival and postdrug survival of first-line immunosuppressive treatments for atopic dermatitis: comparison between methotrexate and cyclosporine. *J Eur Acad Dermatol Venereol*. 2018;32(8):1327-35.
66. Gooderham MJ, Girolomoni G, Moore JO, Silverberg JI, Bissonnette R, Forman S, et al. Durability of response to abrocitinib in patients with moderate-to-severe atopic dermatitis after treatment discontinuation in a phase 2b trial. *Dermatol Ther (Heidelb)*. 2022;12(9):2077-85.
67. Miyamoto S, Imai Y, Natsuaki M, Yamanishi K, Kanazawa N. Long-term remission of atopic dermatitis after discontinuation of dupilumab. *Acta Derm Venereol*. 2022;102:adv00731.
68. Treister AD, Lio PA. Remittive effect of Dupilumab in atopic dermatitis. *Dermatol Ther*. 2018;31(6):e12711.
69. Brown H, Singleton HJ. Atopic eczema and the barriers to treatment adherence for children: a literature review. *Nurs Child Young People*. 2023.
70. Heath MS, Seger EW, Feldman SR. Atopic dermatitis: a look into systemic treatments and adherence considerations. *J Dermatolog Treat*. 2018;29(6):535.
71. Silverberg JI, Guttman-Yassky E, Gadkari A, Kuznik A, Mallya UG, Mastey V, et al. Real-world persistence with dupilumab among adults with atopic dermatitis. *Ann Allergy Asthma Immunol*. 2021;126(1):40-45.
72. Armstrong AW, Huang A, Wang L, Miao R, Patel MY, Gadkari A, et al. Real-world utilization patterns of systemic immunosuppressants among US adult patients with atopic dermatitis. *PLoS One*. 2019;14(1):e0210517.
73. LeBovidge JS, Timmons K, Delano S, Greco KF, DeFreitas F, Chan F, et al. Improving patient education for atopic dermatitis: A randomized controlled trial of a caregiver handbook. *Pediatr Dermatol*. 2021;38(2):396-404.
74. Barbarot S, Stalder JF. Therapeutic patient education in atopic eczema. *Br J Dermatol*. 2014;170 Suppl 1:44-8.
75. Thormann K, Aubert H, Barbarot S, Britsch-Yilmaz A, Chernyshov P, Deleuran M, et al. Position statement on the role of nurses in therapeutic patient education in atopic dermatitis. *J Eur Acad Dermatol Venereol*. 2021;35(11):2143-48.
76. Orenius T, LicPsych, Säilä H, Mikola K, Ristolainen L. Fear of injections and needle phobia among children and adolescents: An overview of psychological, behavioral, and contextual factors. *SAGE Open Nurs*. 2018;4:2377960818759442.

77. Centers for Disease Control and Prevention (CDC). Immunization schedules. Child and adolescent immunization schedule by age. <https://www.cdc.gov/vaccines/schedules/hcp/imz/child-adolescent.html#birth-15>. Published 2023. Accessed August 2023
78. Schäfer A, Kovacs MS, Eder A, Nigg A, Feuchtenberger M. Janus kinase (JAK) inhibitors significantly reduce the humoral vaccination response against SARS-CoV-2 in patients with rheumatoid arthritis. *Clin Rheumatol*. 2022;41(12):3707-14.
79. Garcia-Cirera S, Calvet J, Berenguer-Llargo A, Pradenas E, Marfil S, Massanella M, et al. Glucocorticoids' treatment impairs the medium-term immunogenic response to SARS-CoV-2 mRNA vaccines in Systemic Lupus Erythematosus patients. *Sci Rep*. 2022;12(1):14772.
80. Coulson E, Saravanan V, Hamilton J, Long KS, Morgan L, Heycock C, et al. Pneumococcal antibody levels after pneumovax in patients with rheumatoid arthritis on methotrexate. *Ann Rheum Dis*. 2011;70(7):1289.
81. Park JK, Lee MA, Lee EY, Song YW, Choi Y, Winthrop KL, et al. Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. *Ann Rheum Dis*. 2017;76(9):1559.
82. Deepak P, Kim W, Paley MA, Yang M, Carvidi AB, Demissie EG, et al. Effect of immunosuppression on the immunogenicity of mRNA vaccines to SARS-CoV-2 : A prospective cohort study. *Ann Intern Med*. 2021;174(11):1572-85.
83. van Aalst M, Langedijk AC, Spijker R, de Bree GJ, Grobusch MP, Goorhuis A. The effect of immunosuppressive agents on immunogenicity of pneumococcal vaccination: A systematic review and meta-analysis. *Vaccine*. 2018;36(39):5832-45.
84. van Assen S, Holvast A, Benne CA, Posthumus MD, van Leeuwen MA, Voskuyl AE, et al. Humoral responses after influenza vaccination are severely reduced in patients with rheumatoid arthritis treated with rituximab. *Arthritis Rheum*. 2010;62(1):75-81.
85. Marra F, Lo E, Kalashnikov V, Richardson K. Risk of herpes zoster in individuals on biologics, disease-modifying antirheumatic drugs, and/or corticosteroids for autoimmune diseases: A systematic review and meta-analysis. *Open Forum Infect Dis*. 2016;3(4):ofw205.
86. Shah MA, Beuerlein KG, Jorizzo JL, Feldman SR. Should atopic dermatitis patients starting JAK inhibitors take prophylactic acyclovir? *J Dermatolog Treat*. 2021;32(7):669-72.
87. Winthrop KL, Lebwohl M, Cohen AD, Weinberg JM, Tyring SK, Rottinghaus ST, et al. Herpes zoster in psoriasis patients treated with tofacitinib. *J Am Acad Dermatol*. 2017;77(2):302-09.
88. Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. *Clin Infect Dis*. 2014;58(3):309-18.
89. Papp KA, Haraoui B, Kumar D, Marshall JK, Bissonnette R, Bitton A, et al. Vaccination guidelines for patients with immune-mediated disorders taking immunosuppressive therapies: Executive summary. *J Rheumatol*. 2019;46(7):751-54.
90. Jansen MHA, Rondaan C, Legger GE, Minden K, Uziel Y, Toplak N, et al. EULAR/PRES recommendations for vaccination of paediatric patients with autoimmune inflammatory rheumatic diseases: update 2021. *Ann Rheum Dis*. 2023;82(1):35-47.
91. Blanchard-Rohner G. Vaccination in children with autoimmune disorders and treated with various immunosuppressive regimens: A comprehensive review and practical guide. *Front Immunol*. 2021;12:711637.

92. Olivieri B, Betterle C, Zanoni G. Vaccinations and autoimmune diseases. *Vaccines (Basel)*. 2021;9(8):815.
93. Goyal A, Goyal K, Merola JF. Screening and vaccinations in patients requiring systemic immunosuppression: an update for dermatologists. *Am J Clin Dermatol*. 2015;16(3):179-95.
94. Centers for Disease Control and Prevention (CDC). General Best Practice Guidelines for Immunization. Altered Immunocompetence <https://www.cdc.gov/vaccines/hcp/acip-recs/general-recs/immunocompetence.pdf>. Published 2021. Accessed May 2024
95. Fan R, Cohen JM. Vaccination recommendations for psoriasis and atopic dermatitis patients on biologic therapy: A practical guide. *Yale J Biol Med*. 2022;95(2):249-55.
96. Blauvelt A, Simpson EL, Tying SK, Purcell LA, Shumel B, Petro CD, et al. Dupilumab does not affect correlates of vaccine-induced immunity: A randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis. *J Am Acad Dermatol*. 2019;80(1):158-67.e1.
97. Siegfried EC, Wine Lee L, Spergel JM, Prescilla R, Uppal S, Coleman A, et al. A case series of live attenuated vaccine administration in dupilumab-treated children with atopic dermatitis. *Pediatric Dermatology*. 2024;41(2):204-09.
98. Martinez-Cabriales SA, Kirchhof MG, Constantinescu CM, Murguia-Favela L, Ramien ML. Recommendations for vaccination in children with atopic dermatitis treated with dupilumab: A consensus meeting, 2020. *Am J Clin Dermatol*. 2021;22(4):443-55.
99. Eichenfield LF, Boguniewicz M, Simpson EL, Russell JJ, Block JK, Feldman SR, et al. Translating atopic dermatitis management guidelines into practice for primary care providers. *Pediatrics*. 2015;136(3):554-65.
100. Singh S, Fumery M, Singh AG, Singh N, Prokop LJ, Dulai PS, et al. Comparative risk of cardiovascular events with biologic and synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: A systematic review and meta-analysis. *Arthritis Care & Research*. 2020;72(4):561-76.
101. Low AS, Symmons DP, Lunt M, Mercer LK, Gale CP, Watson KD, et al. Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis. *Ann Rheum Dis*. 2017;76(4):654-60.
102. Hill DA, Spergel JM. The atopic march: Critical evidence and clinical relevance. *Ann Allergy Asthma Immunol*. 2018;120(2):131-37.
103. Hill DA, Grundmeier RW, Ramos M, Spergel JM. Eosinophilic esophagitis Is a late manifestation of the allergic march. *J Allergy Clin Immunol Pract*. 2018;6(5):1528-33.
104. Geba GP, Li D, Xu M, Mohammadi K, Attre R, Ardeleanu M, et al. Attenuating the atopic march: Meta-analysis of the dupilumab atopic dermatitis database for incident allergic events. *Journal of Allergy and Clinical Immunology*. 2023;151(3):756-66.
105. Bantz SK, Zhu Z, Zheng T. The atopic march: Progression from atopic dermatitis to allergic rhinitis and asthma. *J Clin Cell Immunol*. 2014;5(2):202.
106. Nelms K, Keegan AD, Zamorano J, Ryan JJ, Paul WE. THE IL-4 RECEPTOR: Signaling mechanisms and biologic functions. *Annual Review of Immunology*. 1999;17(1):701-38.

Accepted Manuscript

Table 1. Statements for Systemic Therapy Recommendations Reaching Consensus

Statement	Level of consensus (Score 7-9)	Strength of recommendations (Median)	Strength of recommendations (Mean)
Poor adherence to systemic therapy may lead to an inadequate response	100%	9	8.89
Systemic therapy should be considered for those patients with moderate-to-severe atopic dermatitis for whom optimized topical therapy does not adequately improve disease severity and/or quality of life	100%	9	8.78
There is a need for more evidence on specific escalation of therapy across the <2 years, 2–6 years and 6–12 years age groups	100%	9	8.78
Primary care providers play an important role in the management of atopic dermatitis, treating patients with mild-to-moderate disease, referring those with moderate-to-severe disease for specialist care, and providing ongoing maintenance care	100%	9	8.78
Ongoing consultation and dialogue between the primary care provider, families and specialists may be helpful in determining effective treatment approaches	100%	9	8.78
It is important that primary care providers understand atopic	88.89%	9	8.78

dermatitis pathophysiology and diagnosis, management of mild-to-moderate disease, potential adverse events, and when to refer to specialty care			
^a Atopic dermatitis is a disease that may spontaneously improve with age in some patients, so the disease-modifying effects of systemic therapy on atopic dermatitis over the longer term may be difficult to establish	77.77%	9	8.78
^a The impact of early successful management of atopic dermatitis on the natural history of the disorder and development of other atopic and non-atopic morbidities (e.g., neuropsychiatric conditions) during a patient's lifetime is not currently known	77.78%	9	8.78
Reasons for inadequate adherence to treatment are varied but include concerns about adverse effects, inadequate patient or parent/caregiver education, child resistance to treatment, a lack of trust in/rapport with clinician, and high out-of-pocket costs/limitations in access to treatment	100%	9	8.00
Systemic therapy may be considered in some patients requiring higher than recommended use of topical	100%	8	8.00

corticosteroids to control atopic dermatitis			
Clinicians should refer to specific prescribing information, data from clinical trials, and relevant guidelines to guide treatment escalation	100%	8	8.33
Comparative evidence for the use of systemic therapies in atopic dermatitis is limited, especially in children	100%	9	8.33
Treatment may be switched because of inadequate response but there is a need to first consider contributory factors through discussion with the patient/caregivers	88.89%	9	8.44
Treatment taper may be considered when there is a long period of clear or almost clear skin, or in response to tolerability or safety issues	88.89%	9	8.33
Factors to take into consideration in choosing systemic therapy include atopic dermatitis phenotype, the presence of comorbidities, risk–benefit profile of treatments, patient preferences (e.g., oral vs injectable therapy), the need for laboratory monitoring, drug interactions, and access to therapy	88.88%	8	7.89
The use of systemic corticosteroids is associated with frequent disease recurrence and safety risks, and is not generally recommended	88.88%	8	8.00

Discontinuation of treatment may result in disease recurrence	88.88%	8	8.11
Possible effects of systemic treatment on immune response to immunization need to be considered; however, there is limited evidence on co-administration of systemic treatments and vaccines in children with atopic dermatitis	88.88%	8	8.00
The ability to use systemic therapy such as biologics in patients as young as 6 months of age offers the potential for a disease-modifying effect	88.88%	8	8.00
Biologics should be considered first-line systemic therapy in most patients unless contraindicated	77.78%	9	7.33
Biologic therapy does not need to be interrupted for administration of inactivated vaccines but safety of co-administration with live-attenuated vaccines is not known	77.78%	9	8.11
Total steroid burden, including the use of oral and intranasal corticosteroids, should be taken into consideration when assessing patients	77.77%	8	7.67
Conventional systemic therapies may be used off-label	77.77%	8	7.56
Ongoing education and support will help ensure patient comfort with systemic therapy	77.77%	8	7.78

^aStatements required a second round to achieve consensus.

Accepted Manuscript